Two Guidances Focus on ANDA Reconsideration and Viral Safety of Biotech Products

In two recently issued documents, the FDA tackled methods for requesting reconsideration of an ANDA decision and provided final guidance on evaluating the viral safety of biotechnology products.
Source: Drug Industry Daily